Expanded access policy

Tisento is committed to developing effective therapies to address what matters most to patients living with serious diseases. We are currently developing the investigational drug zagociguat for the treatment of the primary mitochondrial disease, MELAS. Our development program includes the clinical trial PRIZM, which is evaluating the safety and effectiveness of zagociguat in participants with MELAS. Click here for more information. 

At this early stage in the program, Tisento does not have an expanded access program that allows use of zagociguat outside of clinical trials.